middle.news
Neurizon sharpens funding position before decisive NUZ-001 ALS data
9:58am on Thursday 5th of November, 2026 AEDT
•
Biotechnology
Read Story
Neurizon sharpens funding position before decisive NUZ-001 ALS data
9:58am on Thursday 5th of November, 2026 AEDT
Key Points
$4.3 million placement secured at 6.8 cents a share
Proposed $2 million Share Purchase Plan on matching terms
All remaining Obsidian convertible notes redeemed
250-participant HEALEY Phase 2/3 trial fully enrolled
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE